Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis
Background and Objective: United States Food and Drug Administration (USFDA) recently approved a novel combination of olanzapine-samidorphan (OLZSAM) for managing olanzapine-associated adverse events (weight gain) in adult patients with schizophrenia and bipolar disorder. To opine about the safety a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-01-01
|
| Series: | Indian Journal of Psychological Medicine |
| Online Access: | https://doi.org/10.1177/02537176231201326 |